Journal of Traditional and Complementary Medicine · 2020 · 18 citations · 19 references
MedicinePharmacologyToxicologyCancer Drug Toxicity ManagementCancer PharmacologyChemotherapyChemotherapy Toxicity ManagementCytotoxic ChemotherapyKidney CancerOncology PharmacologyRenal Cell CarcinomaAnticancer ActivityAnticancer ChemotherapyAnticancer Natural ProductsChemotherapy-associated NephrotoxicityCrude Extract PreparationHerbal NephrotoxicityPlatinum-based Chemotherapy Renal ToxicityToxicity Of Medicinal Plants
BACKGROUND: (crude aqueous extract-CAE) to reverse the toxic effects. AIM: To evaluate the nephroprotective activity of CAE and its fractions in cisplatin-induced nephrotoxicity and to assess whether they compromise the anticancer efficacy of cisplatin. MATERIALS AND METHODS: Cisplatin-induced renal damage was induced in Ehrlich Ascites Carcinoma (EAC) bearing mice during mild phase of tumor growth. CAE and its butanol (BF) and aqueous (AF) fractions were administered orally from the 5th day for five days. Nephroprotective potential (serum urea, creatinine, renal histology) and effect of VC on cisplatin anticancer efficacy (tumor volume, viable tumor cells, percentage increase in life span (% ILS)) were calculated. RESULT: CAE and its fractions significantly reversed the cisplatin-induced renal damage. CAE and BF treated animals showed regeneration of 50%-75% of proximal tubular cells. Compared to EAC control mice, the % ILS of the cisplatin-treated group was 244% and it was further extended to 379% after CAE administration. The % ILS in the CAE treated group was 1.6 times higher than the cisplatin alone treated group. GC-MS study showed the presence of astaxanthin and betulin. CONCLUSION: CAE of VC reverses cisplatin-induced kidney damage as well as regenerates proximal tubular epithelial cells, without compromising the anticancer effect of cisplatin. When CAE was further fractionated, the nephroprotective activity was retained, but the beneficial anticancer effect of cisplatin was compromised.
19
Marieke Kruidering, Bob van de Water, Emile de Heer et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 325 citations
Long–Term Renal Outcomes after Cisplatin Treatment
Sheron Latcha, Edgar A. Jaimes, Sujata Patil et al. · Clinical Journal of the American Society of Nephrology · 2016 · 255 citations · Full text
Medicine, Nephrology, Oncology +17